1 Min Read
Sept 11 (Reuters) - Immunomedics Inc:
* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.